MX347784B - Nueva terapia para la amiloidosis asociada a transtiretina. - Google Patents
Nueva terapia para la amiloidosis asociada a transtiretina.Info
- Publication number
- MX347784B MX347784B MX2014004863A MX2014004863A MX347784B MX 347784 B MX347784 B MX 347784B MX 2014004863 A MX2014004863 A MX 2014004863A MX 2014004863 A MX2014004863 A MX 2014004863A MX 347784 B MX347784 B MX 347784B
- Authority
- MX
- Mexico
- Prior art keywords
- transthyretin
- associated amyloidosis
- inhibitor
- new therapy
- comt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382326 | 2011-10-24 | ||
| PCT/EP2012/070945 WO2013060668A1 (en) | 2011-10-24 | 2012-10-23 | New therapy for transthyretin-associated amyloidosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014004863A MX2014004863A (es) | 2014-05-27 |
| MX347784B true MX347784B (es) | 2017-05-12 |
Family
ID=47076222
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017006182A MX385516B (es) | 2011-10-24 | 2012-10-23 | Nueva terapia para la amiloidosis asociada a transtiretina. |
| MX2014004863A MX347784B (es) | 2011-10-24 | 2012-10-23 | Nueva terapia para la amiloidosis asociada a transtiretina. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017006182A MX385516B (es) | 2011-10-24 | 2012-10-23 | Nueva terapia para la amiloidosis asociada a transtiretina. |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9610270B2 (OSRAM) |
| EP (1) | EP2770988B1 (OSRAM) |
| JP (1) | JP6068484B2 (OSRAM) |
| KR (1) | KR102017354B1 (OSRAM) |
| CN (1) | CN103889407B (OSRAM) |
| AU (2) | AU2012327275B2 (OSRAM) |
| BR (1) | BR112014009322B1 (OSRAM) |
| CA (1) | CA2852808C (OSRAM) |
| CL (1) | CL2014000893A1 (OSRAM) |
| CY (1) | CY1118151T1 (OSRAM) |
| ES (1) | ES2593038T3 (OSRAM) |
| IL (1) | IL231907B (OSRAM) |
| MX (2) | MX385516B (OSRAM) |
| PL (1) | PL2770988T3 (OSRAM) |
| PT (1) | PT2770988T (OSRAM) |
| RU (2) | RU2747536C2 (OSRAM) |
| SG (2) | SG10201609933WA (OSRAM) |
| WO (1) | WO2013060668A1 (OSRAM) |
| ZA (1) | ZA201402546B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103889407B (zh) * | 2011-10-24 | 2017-03-15 | 索姆创新生物技术公司 | 用于甲状腺素运载蛋白相关的淀粉样变性的疗法 |
| DK3185957T3 (da) * | 2014-08-29 | 2022-08-29 | Alnylam Pharmaceuticals Inc | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| MX2020009548A (es) * | 2018-03-12 | 2021-01-08 | Corino Therapeutics Inc | Terapia combinada para la amiloidosis ttr. |
| CA3141998A1 (en) * | 2019-05-31 | 2020-12-03 | Plex Pharmaceuticals, Inc. | Pharmacological agents for treating protein aggregation diseases of the eye |
| CN114324693B (zh) * | 2022-01-14 | 2023-01-13 | 大连博源医学科技有限公司 | 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法 |
| JP2025536853A (ja) * | 2022-10-10 | 2025-11-07 | コリノ セラピューティクス，インク． | 放出調節トルカポン処方剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744368A (en) | 1993-11-04 | 1998-04-28 | Research Foundation Of State University Of New York | Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR) |
| AU5727798A (en) | 1996-12-23 | 1998-07-17 | Texas A & M University, The | Anti-amyloidogenic agents |
| FI20002044A0 (fi) * | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
| CA2440293C (en) | 2001-03-15 | 2012-01-24 | Proteotech, Inc. | Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders |
| JP2006510722A (ja) | 2002-01-29 | 2006-03-30 | プロテミックス コーポレイション リミティド | 細胞障害性タンパク質コンフォーマーの抑制 |
| US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| CN1921856A (zh) * | 2004-02-20 | 2007-02-28 | 诺瓦提斯公司 | 用于治疗神经变性疾病和认知障碍的dpp－iv抑制剂 |
| BRPI0507905A (pt) | 2004-02-20 | 2007-07-10 | Novartis Ag | uso de compostos orgánicos |
| CN1976693A (zh) * | 2004-05-20 | 2007-06-06 | 斯克里普斯研究所 | 转甲状腺素蛋白的稳定 |
| ES2339790T3 (es) | 2004-08-30 | 2010-05-25 | Seo Hong Yoo | Efecto neuroprotector de udca solubilizado en modelo isquemico focal. |
| GB2429645A (en) | 2006-03-10 | 2007-03-07 | Sekhsaria Chemicals Ltd | Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent |
| US20120016037A1 (en) | 2006-07-24 | 2012-01-19 | Frank Toppo | Method for prevention and treatment of Alzheimers |
| GB0718718D0 (en) | 2007-09-25 | 2007-11-07 | Pentraxin Therapeutics Ltd | Compound and use thereof |
| DE102010010572A1 (de) | 2010-03-08 | 2011-09-08 | Mahle International Gmbh | Trockenseparator |
| CN103889407B (zh) * | 2011-10-24 | 2017-03-15 | 索姆创新生物技术公司 | 用于甲状腺素运载蛋白相关的淀粉样变性的疗法 |
-
2012
- 2012-10-23 CN CN201280051812.8A patent/CN103889407B/zh not_active Expired - Fee Related
- 2012-10-23 ES ES12778323.1T patent/ES2593038T3/es active Active
- 2012-10-23 BR BR112014009322-9A patent/BR112014009322B1/pt active IP Right Grant
- 2012-10-23 JP JP2014536290A patent/JP6068484B2/ja active Active
- 2012-10-23 KR KR1020147010767A patent/KR102017354B1/ko active Active
- 2012-10-23 SG SG10201609933WA patent/SG10201609933WA/en unknown
- 2012-10-23 WO PCT/EP2012/070945 patent/WO2013060668A1/en not_active Ceased
- 2012-10-23 PT PT127783231T patent/PT2770988T/pt unknown
- 2012-10-23 PL PL12778323T patent/PL2770988T3/pl unknown
- 2012-10-23 AU AU2012327275A patent/AU2012327275B2/en not_active Ceased
- 2012-10-23 MX MX2017006182A patent/MX385516B/es unknown
- 2012-10-23 MX MX2014004863A patent/MX347784B/es active IP Right Grant
- 2012-10-23 RU RU2017119539A patent/RU2747536C2/ru active
- 2012-10-23 EP EP12778323.1A patent/EP2770988B1/en active Active
- 2012-10-23 US US14/353,459 patent/US9610270B2/en active Active
- 2012-10-23 SG SG11201401215VA patent/SG11201401215VA/en unknown
- 2012-10-23 CA CA2852808A patent/CA2852808C/en active Active
- 2012-10-23 RU RU2014114930A patent/RU2623062C2/ru active
-
2014
- 2014-04-03 IL IL231907A patent/IL231907B/en active IP Right Grant
- 2014-04-08 ZA ZA2014/02546A patent/ZA201402546B/en unknown
- 2014-04-09 CL CL2014000893A patent/CL2014000893A1/es unknown
-
2016
- 2016-09-20 CY CY20161100934T patent/CY1118151T1/el unknown
-
2017
- 2017-03-02 US US15/448,054 patent/US10045956B2/en active Active
- 2017-04-21 AU AU2017202670A patent/AU2017202670B2/en not_active Ceased
-
2018
- 2018-08-13 US US16/101,882 patent/US10449169B2/en active Active
-
2019
- 2019-09-12 US US16/569,055 patent/US10786473B2/en active Active
-
2020
- 2020-08-28 US US17/005,893 patent/US11564899B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX347784B (es) | Nueva terapia para la amiloidosis asociada a transtiretina. | |
| CL2012003281A1 (es) | Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica. | |
| CO2019005287A2 (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
| CL2015001377A1 (es) | Inhbibidores de bmi-1 primidinas sustituidas inversas | |
| BR112012011086A2 (pt) | uso de betanecol para o tratamento de xerostomia | |
| MX2020003139A (es) | Composicion y metodo para ayudar a dormir. | |
| CL2016000042A1 (es) | Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas. | |
| GT201300320A (es) | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer. | |
| CR20140388A (es) | Compuestos terapeuticamente activos y sus métodos de uso | |
| CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
| UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
| MX2015011466A (es) | Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora. | |
| BR112014028755A2 (pt) | composição de argamassa de poliuretano, processo para preparação da composição de argamassa de poliuretano, e, uso de uma composição de argamassa de poliuretano. | |
| DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
| CL2008003041A1 (es) | Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
| CL2016001266A1 (es) | Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo. | |
| BR112016017402A2 (pt) | fusões anti-pcsk9~glp-1 e métodos para uso | |
| CL2012002173A1 (es) | Combinacion de al menos un estimulador o activador de la sgc con un inhibidor de la pde5; formulacion farmaceutica; y uso para el tratamiento de la fibrosis quistica. | |
| CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
| MX2020002823A (es) | Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia. | |
| BR112014030406A8 (pt) | combinação de canabidiol fitocanabinoide com hipotermia terapêutica, e, uso de uma combinação | |
| CL2016001362A1 (es) | Composiciones y métodos para reducir eventos adversos cardiovasculares graves | |
| PH12018500391A1 (en) | Single-use multi-layered ticket and redeeming technique | |
| CR20160316A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| CL2016001192A1 (es) | Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |